Search

Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.

Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.

• News
• Usher syndrome

Our monthly e-Newsletter featuring the latest updates from Retina UK.

• e-Newsletter
• Audio
• Video

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

• e-Newsletter
• Audio
• Written

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

• e-Newsletter
• Audio
• Written

Retina UK is delighted to have awarded a new three-year research grant to Prof Majlinda Lako at Newcastle University for a project entitled: To establish AAV.PRPF31 gene augmentation in PRPF31-deficient RPE and photoreceptor cells and assess its efficacy in restoring RPE and photoreceptor function.

• News
• Retinitis pigmentosa

Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).

• News

Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.

• News
• Leber congenital amaurosis (LCA)

We are proud to launch our new Young Persons Project, which will play a significant role in providing impactful and timely support for young people with inherited sight loss and mental health challenges, across the UK.

• News
• Retinitis pigmentosa